Keros Therapeutics, Inc. (KROS) income statement
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$12.00+0.69 (+6.10%)
Close on Nov 18, 2026Market cap $237.93MP/E –Yield –
Keros Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -698.0%
- Net margin
- -572.1%
- Return on equity, FY2025
- 19.9%
Financial strength
- Current ratio
- 21.96
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2119.7%
Valuation
- P/E ratio
- –
- Price to sales
- 16.37
- Price to book
- 0.91
- Dividend yield
- –
See a number that looks wrong?